Oventus Medical Limited has signed further material agreements with US sleep medicine groups, Delaware Sleep Disorder Centres and Reliable Respiratory. The two companies will adopt the Company's O2Vent® Sleep Treatment Platform and `lab in lab' business model for the treatment of obstructive sleep apnoea (OSA) across a total of 10 facilities divided between the two companies. Under the agreements, Oventus is the exclusive supplier of dental sleep services for the treatment of OSA. The agreements initially cover 10 new sites: three sites in Delaware with Delaware Sleep Disorder Centres, and seven sites in New England. A minimum monthly quota of 20 O2Vent® devices will be delivered to patients per site. The agreements will be officially launched as soon as the O2Vent® Optima oral device has received regulatory clearance from the US FDA (application pending approval) which Oventus expects to receive in second half calendar 2019.